問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberCO44657
Active

2023-11-01 - 2030-12-31

Phase III

Not yet recruiting4

Recruiting2

ICD-10C50.011

Malignant neoplasm of nipple and areola, right female breast

ICD-10C50.012

Malignant neoplasm of nipple and areola, left female breast

ICD-10C50.019

Malignant neoplasm of nipple and areola, unspecified female breast

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9174.0

Malignant neoplasm of female breast, nipple and areola

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator YEN-SHEN LU Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jih-Hsiang Lee Division of Hematology & Oncology

Co-Principal Investigator

  • 吳旭 Division of Hematology & Oncology
  • 郭宇如 Division of Hematology & Oncology
  • 呂庭毅 Division of Hematology & Oncology
  • 陳敬左 Division of Hematology & Oncology
  • 李明璟 Division of Hematology & Oncology
  • 楊博鈞 Division of Hematology & Oncology
  • 吳宗哲 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ling-Ming Tseng Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator HWEI-CHUNG WANG Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator 鍾奇峰 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator Chih-Chiang Hung Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    1050 participants